ATE330002T1 - Verfahren zur herstellung von membranvesikeln - Google Patents

Verfahren zur herstellung von membranvesikeln

Info

Publication number
ATE330002T1
ATE330002T1 AT01943246T AT01943246T ATE330002T1 AT E330002 T1 ATE330002 T1 AT E330002T1 AT 01943246 T AT01943246 T AT 01943246T AT 01943246 T AT01943246 T AT 01943246T AT E330002 T1 ATE330002 T1 AT E330002T1
Authority
AT
Austria
Prior art keywords
membrane vesicles
preparations
methods
relates
present
Prior art date
Application number
AT01943246T
Other languages
English (en)
Inventor
Henry Lamparski
Curtis Ruegg
Pecq Jean-Bernard Le
Di-Hwei Hsu
Jenq-Yuan Yao
Original Assignee
Exothera L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/561,205 external-priority patent/US6812023B1/en
Application filed by Exothera L L C filed Critical Exothera L L C
Application granted granted Critical
Publication of ATE330002T1 publication Critical patent/ATE330002T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
    • C23C16/44—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
    • C23C16/4401—Means for minimising impurities, e.g. dust, moisture or residual gas, in the reaction chamber
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C16/00—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes
    • C23C16/44—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
    • C23C16/50—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges
    • C23C16/505—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges using radio frequency discharges
    • C23C16/509—Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges using radio frequency discharges using internal electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J37/00—Discharge tubes with provision for introducing objects or material to be exposed to the discharge, e.g. for the purpose of examination or processing thereof
    • H01J37/32—Gas-filled discharge tubes
    • H01J37/32431—Constructional details of the reactor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Metallurgy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Plasma & Fusion (AREA)
  • Materials Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
AT01943246T 2000-04-27 2001-04-11 Verfahren zur herstellung von membranvesikeln ATE330002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/561,205 US6812023B1 (en) 2000-04-27 2000-04-27 Methods of producing membrane vesicles
US09/780,748 US20040241176A1 (en) 2000-04-27 2001-02-09 Method of producing membrane vesicles

Publications (1)

Publication Number Publication Date
ATE330002T1 true ATE330002T1 (de) 2006-07-15

Family

ID=27072576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943246T ATE330002T1 (de) 2000-04-27 2001-04-11 Verfahren zur herstellung von membranvesikeln

Country Status (11)

Country Link
US (1) US20040241176A1 (de)
EP (1) EP1278825B1 (de)
JP (1) JP2003531864A (de)
CN (1) CN1426461A (de)
AT (1) ATE330002T1 (de)
AU (1) AU6587301A (de)
CA (1) CA2407225A1 (de)
DE (1) DE60120683D1 (de)
EA (1) EA005425B1 (de)
IL (1) IL152472A0 (de)
WO (1) WO2001082958A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356291B1 (de) 2000-12-06 2011-05-04 Ecole Polytechnique Fédérale de Lausanne (EPFL) Verfahren zur herstellung eines bioanalytischen reagenzes, nachweisverfahren beruhend auf der verwendung des bioanalytischen reagenz, sowie dessen verwendung
CA2454756C (en) 2001-08-17 2014-02-18 Anosys, Inc. Methods and compounds for the targeting of protein to exosomes
DK1448229T3 (da) * 2001-11-29 2010-03-08 Dandrit Biotech As Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
AU2003214566A1 (en) * 2002-03-14 2003-09-22 Anosys, Inc. Functionalization of T cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
KR20030085659A (ko) * 2002-04-30 2003-11-07 동부한농화학 주식회사 암 치료용 엑소좀 및 그를 이용한 암 백신
KR100519384B1 (ko) * 2002-08-13 2005-10-06 (주)누백스 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도
US7914792B2 (en) 2003-02-14 2011-03-29 Exothera L.L.C. Methods and compounds for raising antibodies and for screening antibody repertoires
FR2852393B1 (fr) * 2003-03-14 2007-04-13 Univ Aix Marseille Ii Methode de detection et d'analyse d'organelle immobilises sur biopuce et leurs applications
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US20080268429A1 (en) * 2004-06-02 2008-10-30 Sourcepharm, Inc. Rna - Containing Microvesicles and Methods Therefor
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
US9599611B2 (en) 2005-04-25 2017-03-21 Trustees Of Boston University Structured substrates for optical surface profiling
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
EP2696203A3 (de) 2007-08-16 2014-05-28 The Royal Institution for the Advancement of Learning/McGill University Tumorzellen-abgeleitete Mikrovesikel
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
US10545149B2 (en) * 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
US9487837B2 (en) 2008-10-06 2016-11-08 Morehouse School Of Medicine Exosome-mediated diagnosis of hepatitis virus infections and diseases
CN102308004A (zh) 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
WO2010065968A1 (en) * 2008-12-05 2010-06-10 Myriad Genetics, Inc. Cancer detection markers
US9835618B1 (en) * 2009-02-06 2017-12-05 Los Alamos National Security, Llc Discovery, detection and use of biomarkers
EP2419144B1 (de) 2009-04-17 2019-08-07 Oxford University Innovation Limited Zusammensetzung zur abgabe eines genetischen materials
JP5667180B2 (ja) 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
KR20120081972A (ko) 2009-07-02 2012-07-20 아이티에이치 임뮨 세라피 홀딩스 에이비 엑소좀에 기초한 암의 치료
IN2012DN00866A (de) * 2009-07-16 2015-07-10 Gen Hospital Corp
WO2011031892A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
EP2578236B1 (de) 2010-05-26 2016-03-30 Micromedmark Biotech Co., Ltd Herstellung von mikrovesikel-si-rna-komplexen und ihre verwendung bei der behandlung von aids
US9376679B2 (en) 2010-05-26 2016-06-28 Micromedmark Biotech Co. Ltd. Microvesicles carrying small interfering RNAs, preparation methods and uses thereof
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2638057B1 (de) 2010-11-10 2019-03-06 Exosome Diagnostics, Inc. Verfahren zur isolierung von nukleinsäure enthaltenden partikeln und extraktion von nukleinsäuren daraus
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
ITNA20110012A1 (it) * 2011-03-14 2012-09-15 Amal Raj Delfin Albert Procedura di isolamento e di purificazione degli esosomi urinari per la ricerca di biomarcatori proteici
HK1199754A1 (en) * 2011-09-22 2015-07-17 Universidad De Los Andes Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2013109713A1 (en) 2012-01-18 2013-07-25 The General Hospital Corporation Targeting rnas to microvesicles
CN103479682B (zh) * 2012-06-14 2015-03-11 苏州恒宇生物科技有限公司 一种植物来源活性成分-纳米级膜性囊泡的制备方法
WO2014028763A1 (en) 2012-08-15 2014-02-20 The University Of Chicago Exosome-based therapeutics against neurodegenerative disorders
US20140186293A1 (en) * 2012-12-31 2014-07-03 University Of Louisville Research Foundation, Inc. Immunoglobulin-bound extracellular vesicles and uses thereof
SG11201508433TA (en) 2013-04-12 2015-11-27 Andaloussi Samir El Therapeutic delivery vesicles
CN104274828B (zh) * 2013-07-04 2017-11-17 复旦大学 IFN‑α处理细胞所分泌外体在制备抑制肝炎病毒的药物中的应用
JP6547625B2 (ja) 2013-10-25 2019-07-24 凸版印刷株式会社 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法
CN106573220B (zh) 2014-07-24 2019-08-16 凸版印刷株式会社 脂质膜结构体、脂质膜结构体固定化载体、及胞体的融合方法
US10329323B2 (en) * 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
EP3353528B1 (de) 2015-09-22 2023-11-29 Trustees of Boston University Multiplexierte phänotypisierung von nanovesikeln
CA3001065A1 (en) * 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
EP3411713B1 (de) 2016-02-05 2021-06-30 NanoView Biosciences, Inc. Detektion von exosomen mit oberflächenmarkierungen
WO2017204187A1 (ja) 2016-05-24 2017-11-30 公益財団法人がん研究会 細胞外小胞回収方法及び細胞外小胞用容器
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
US20200046766A1 (en) * 2016-10-13 2020-02-13 Vbc Holdings Llc Cancer stem cell exosomes
CN110073195B (zh) * 2016-11-23 2022-03-29 阿曼·沙马 提取外泌体以及与之结合的生物大分子的方法以及试剂盒
CN107907689A (zh) * 2017-10-10 2018-04-13 北京大学 外泌体蛋白cd5l的检测方法
NL2019814B1 (en) * 2017-10-26 2019-05-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Methods for producing a MHC multimer.
CA3094577A1 (en) 2018-03-30 2019-10-03 Exosomics S.p.A. Use of hollow fibers to obtain blood or a blood derivative impoverished from blood cells and platelets derived extracellular vesicles
US12510462B2 (en) 2018-06-01 2025-12-30 Unchained Labs Compositions, systems, and methods for enhanced label-free and fluorescence-based detection of nanoparticles
JP7376887B2 (ja) * 2019-08-20 2023-11-09 Ｊｆｅエンジニアリング株式会社 動物細胞の増殖促進方法、連続培養方法及び連続培養装置
JP7513869B2 (ja) 2020-03-23 2024-07-10 澁谷工業株式会社 エクソソーム抽出装置およびエクソソームの抽出方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
FR2785543B1 (fr) * 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations

Also Published As

Publication number Publication date
US20040241176A1 (en) 2004-12-02
EA005425B1 (ru) 2005-02-24
DE60120683D1 (de) 2006-07-27
WO2001082958A2 (en) 2001-11-08
EA200201150A1 (ru) 2003-04-24
EP1278825A2 (de) 2003-01-29
IL152472A0 (en) 2003-05-29
EP1278825B1 (de) 2006-06-14
CN1426461A (zh) 2003-06-25
JP2003531864A (ja) 2003-10-28
WO2001082958A3 (en) 2002-04-18
AU6587301A (en) 2001-11-12
CA2407225A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
DE60120683D1 (de) Verfahren zur herstellung von membranvesikeln
EP0134385B1 (de) Protein mit Zellwachstumsstimulierender Wirkung, dessen Zusammensetzung und Verfahren zu seiner Herstellung
WO2001068811A3 (de) Verfahren zur in vitro-herstellung von dreidimensionalem, vitalem knorpel- oder knochengewebe und dessen verwendung als transplantationsmaterial
DE69839443D1 (de) Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
DE3855921D1 (de) Verfahren und Desoxyribonukleinsäure zur Herstellung von Gewebefaktor-Protein
IL173399A (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medical products for producing recombinant proteins in vivo
EP1789537A2 (de) Konditioniertes medium mit wnt-proteinen zur förderung der reparatur von beschädigtem gewebe
DE69532159D1 (de) Verfahren zur beschleunigung der wundheilung durch stimulierung des fibroblasten-und keratinozyten-wachstums
DE69735851D1 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
DE60003580D1 (de) MEDIZINISCHE VORRICHTUNG mit nukleinsäurehaltiger synthetischer Oberfläche zur in-vivo Induktion seiner Endothelialisierung
ATE97316T1 (de) Kosmetisches mittel und zusammensetzung zur behandlung der haut.
Takano et al. Pressure-induced apoptosis in human lymphoblasts
ATE92720T1 (de) Verfahren zur modifizierung von molke.
Hade et al. Significant enhancement of fibroblast migration, invasion, and proliferation by exosomes loaded with human fibroblast growth factor 1
DE60021404D1 (de) System zur herstellung von proteinen
US11174463B2 (en) Method for the production of hair follicles and de novo papillae, and use thereof for in vitro tests and in vivo implants
WO2008028882A1 (en) A method for producing langerhans cells and/or dermal/interstitial dentritic cells from cd14+ monocytes
JPS61128974A (ja) 人工基底膜及びその製造方法
DE69812645D1 (de) Verfahren zur herstellung von kontrastmitteln
ATE241387T1 (de) Verfahren zur in vivo dns-verabreichung durch verwendung eines nadelfreien geräts
DE69920216D1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
SE9300509D0 (sv) Peg treatment
Akimoto et al. Reconstruction of basement membrane in recombinants of epidermis and dermis of chick embryonic skin in vitro: An electron microscopic study
Cooley Cell-based treatments for hair loss: research update on “hair cloning”
Darnule et al. Antiserum to surface antigens as a marker for cultured rat lung endothelial cells (1)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties